Question-and-Answer Session
Operator
Thank you. (Operator instructions) Our first question today is from Ted Tenthoff from Piper Jaffray.
Ted Tenthoff – Piper Jaffray
Great, thank you very much for taking the time to run through such a thorough update on the company. There's a lot going on. I'll just focus in first on 543, if I may. I know that as we talked earlier this calendar year that we had been looking at what I thought was maybe a bit of a broader or a faster development plan there going into Phase 2. So, can you just kind of take a step back, go into a little bit more detail on what you're seeing with that compound, and really the reasoning behind the studies that you are picking out?
John Yates
Yes. So, 543 has continued very well in the initial Phase 1 study. The expansion cohort is close to complete enrollment now. When you get into combination studies, obviously there is a step-wise process in terms of dose escalation with combination drugs before we can go into expansion phases in combination. And all of that takes time. Those initial phases tend to be with relatively few centers. But I would say that we're very pleased with the progress that we're making in those Phase 1b/2 combination trials. And, as I say, we have a lot of investigator enthusiasm behind the product now. So I think that as we learn more about 543, its activity and really how it stacks up relative to lapatinib in particular, I think we ourselves feel that the potential for this drug's success is very high, and I think that that will translate into rapid enrollment in the studies going forward.
Ted Tenthoff – Piper Jaffray
Great, that’s really helpful. And just one quick follow-up, can you give us a sense of what the two – what some of the lead horses are in the new development programs that you might potentially advance later this year?
Bob Conway
Ted, you're going to have to be patient. We want to come out with those later in the year, and I think they're both exciting programs, but we probably won't announce those until the fourth quarter.
Ted Tenthoff – Piper Jaffray
Look forward to it, thanks.
Bob Conway
Okay.
Operator
And moving on, our next question is from Tim Lugo from William Blair.
Bob Conway
Hi, Tim.
Tim Lugo – William Blair
- To read the full transcript on Seeking Alpha, click here »
